pcrh

>1. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. Conclusions: SSRIs might have statistically significant effects on depressive symptoms, but *all trials were at high risk of bias and the clinical significance seems questionable*. SSRIs significantly increase the risk of both serious and non-serious adverse events. The potential small beneficial effects seem to be outweighed by harmful effects.

>2. The trouble with antidepressants: why the evidence overplays benefits and underplays risks. Widespread prescribing has not reduced mental disability or suicide, raising questions about the assessment of evidence on effectiveness and safety of antidepressants

>3. In search of a dose–response relationship in SSRIs—a systematic review, meta-analysis, and network meta-analysis. Conclusions: There is no conclusive level I or level II evidence of a clinically meaningful dose–response relationship of SSRIs as a group or of single substances. High SSRI doses are not recommended as routine treatment.

>4 The serotonin theory of depression: a systematic umbrella review of the evidence "We did not identify *any* trials using ‘active placebo’ or ‘no intervention’ as control interventions. "

EU laws are adjudicated by the Court of Justice of the European Union.

>At baseline, 184 (14%) of 1280 children with successful FEV1 measurement in London had a clinically low FEV1 (pre-bronchodilator FEV1 <80% of predicted value) compared with 126 (9%) of 1339 children in Luton (appendix p 8). At the end of the study, these values had dropped to 51 (9%) of 585 children in London and 41 (7%) of 606 children in Luton (appendix p 8).

So the proportion of children with low lung function dropped from 14% to 9% in London, and from 9% to 7% at the comparator site in Luton. It's not that much different, though any improvement is obviously welcome.